Role of major histocompatibility complex class-I molecules in tumor rejection. New insights from studies with synthetic peptides and transgenic mice.
Höglund
P
P
Department of Tumor Biology, Karolinska Institutet, Stockholm, Sweden.
Ljunggren
H G
HG
Kärre
K
K
Jay
G
G
D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D003602:Cytotoxicity, Immunologic; D006084:Graft Rejection / Q000276:immunology; D006183:H-2 Antigens / Q000276:immunology; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D007157:Immunologic Surveillance; D007694:Killer Cells, Natural / Q000276:immunology; D051379:Mice; D008822:Mice, Transgenic / Q000276:immunology; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000276:immunology*; D009374:Neoplasms, Experimental / Q000276:immunology; D010446:Peptide Fragments / Q000138:chemical synthesis / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D000951:Antigens, Neoplasm; D006183:H-2 Antigens; D015395:Histocompatibility Antigens Class I; D010446:Peptide Fragments